Merck & Company
NYSE: MRK
Merck is a global pharmaceutical company that develops and sells prescription medicines, vaccines and animal health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiovascular conditions and other major therapeutic areas. Keytruda, its leading cancer immunotherapy, is a major revenue driver, while Gardasil is another important vaccine franchise. Its Animal Health business provides medicines, vaccines and healthcare solutions for livestock and companion animals.
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Employees
- 75,000
- Founded
- 1891
- Website
- merck.com ↗
The forecast figures are tipranks’s, read on 2026-11-16 and linked below.
The company facts and financials are CNN Business’s, read on 2026-11-16 and linked below.
Merck & Company forecast
The forecast in short
tipranks records 22 analyst ratings on Merck & Company and summarises them as “Moderate Buy”. Their average 12-month price target is USD 162.14 (9.73% Upside). Its tipranks score is 8 out of 10 — Outperform. These are tipranks’s figures as read on 2026-11-16, not CariBroker’s own view, and nothing here is advice to buy or sell.
Market cap
USD 339.66 B
≈ RM 1.39 T
Share price
USD 137.78
≈ RM 563.60 · 18 Nov close
#40World ranking
tipranks score
Outperform
Analyst ratings
Moderate Buy
- Buy1568%
- Hold732%
- Sell00%
tipranks’s own summary of the 22 ratings above.
12 months price forecast
USD 162.14 9.73% Upside
As tipranks publishes it. CariBroker has not recalculated any of it.
Financials
Q3 earnings, quarter ending Sep 29, 2026
| Measure | Q3 2026 | 1-year change |
|---|---|---|
| Total revenue | 18.12B | 11.02% up |
| Net income | 5.07B | 70.94% up |
| Earnings per share | 2.04 | 11.74% down |
| Net profit margin | 27.95% | 16.99% down |
| Free cash flow | 5.52B | 202.52% up |
| Debt-to-equity ratio | 1.20 | 50.12% up |
Revenue and net income, last 4 quarters
Total revenueNet income
Analyst profiles: who made each call, and when
| Analyst | From | Position | Target price | Dated |
|---|---|---|---|---|
| Carter Gould | Cantor Fitzgerald | Hold | USD 155 | 2026-11-11 |
| Louise Chen | Scotiabank | Buy | USD 180 | 2026-11-10 |
| Trung Huynh | RBC Capital | Hold | USD 140 | 2026-11-05 |
| Elmar Kraus | DZ BANK AG | Hold | USD 153 | 2026-11-03 |
| Daina Graybosch | Leerink Partners | Buy | USD 162 | 2026-11-02 |
Show all 27
| Analyst | From | Position | Target price | Dated |
|---|---|---|---|---|
| Ilya Zubkov | Freedom Capital Markets | Hold | USD 140 | 2026-11-02 |
| Jason Gerberry | Bank of America Securities | Buy | USD 165 | 2026-10-30 |
| Evan Seigerman | BMO Capital | Buy | USD 170 | 2026-10-30 |
| Terence Flynn | Morgan Stanley | Buy | USD 174 | 2026-10-30 |
| Chris Schott | J.P. Morgan | Buy | USD 175 | 2026-10-30 |
| Vamil Divan | Guggenheim | Buy | USD 171 | 2026-10-29 |
| Emily Field | Barclays | Buy | USD 180 | 2026-10-28 |
| Geoff Meacham | Citi | Hold | USD 145 | 2026-10-27 |
| Mohit Bansal | Wells Fargo | Buy | USD 165 | 2026-10-26 |
| Courtney Breen | Bernstein | Hold | USD 105 | 2026-10-25 |
| Michael Yee | UBS | Buy | USD 175 | 2026-10-24 |
| Asad Haider | Goldman Sachs | Buy | USD 155 | 2026-10-22 |
| Steve Scala | TD Cowen | Hold | USD 155 | 2026-09-22 |
| Nico Chen | DBS | Buy | USD 180 | 2026-09-11 |
| Rajesh Kumar | HSBC | Buy | USD 172 | 2026-09-10 |
| Alexandria Hammond | Wolfe Research | Buy | USD 180 | 2026-08-25 |
| Jasper Hellweg | Argus Research | Buy | USD 170 | 2026-08-24 |
| Luisa Hector | Berenberg Bank | Hold | USD 127 | 2026-08-05 |
| Unknown Analyst | Jefferies | Buy | USD 138 | 2026-05-19 |
| Hans Engel | Erste Group | Hold | N/A | 2026-05-05 |
| Natalya Davies | Rothschild & Co Redburn | Buy | USD 179 | 2026-04-17 |
| James Shin | Deutsche Bank | Buy | USD 150 | 2026-02-13 |
Investment strengths
Diversified product growth
Revenue growth is supported by multiple therapeutic and animal-health franchises rather than a single product. Continued contributions from new products, oncology and animal health broaden the earnings base and provide durable commercial momentum over the next several quarters.
Pipeline strength
Late-stage clinical and regulatory progress strengthens Merck’s ability to replenish growth as mature products age. Positive results across oncology, vaccines and pulmonary hypertension diversify future launch opportunities and improve the durability of the portfolio.
Strong cash generation
Substantial operating and free cash flow gives Merck capacity to fund research, launches, capital needs, dividends and business development internally. Strong cash conversion supports financial resilience even while recent free-cash-flow growth has moderated.
People also ask
What is the 12-month price target for Merck & Company (MRK)?
tipranks publishes an average 12-month price target of USD 162.14 (9.73% Upside), as read on 2026-11-16. The highest target is USD 180 and the lowest is USD 105. A price target is an analyst’s estimate of where a share might trade, not a promise, and CariBroker gives no investment advice.
How many analysts cover Merck & Company (MRK)?
tipranks records 22 analyst ratings: 15 buy, 7 hold and 0 sell, which it summarises as “Moderate Buy”, as read on 2026-11-16.
What is the tipranks score for Merck & Company (MRK)?
tipranks scores it 8 out of 10 and calls that “Outperform”, as read on 2026-11-16. The score is tipranks’s, not CariBroker’s, and CariBroker does not rate listed shares.
Is this CariBroker’s own forecast for Merck & Company?
No. Every figure on this page is published by tipranks, copied on 2026-11-16 with a link to the original, and not recalculated. CariBroker checks financial companies in Malaysia against the public registers; it makes no forecast of its own and holds no licence to advise on securities.
Disclaimer
CariBroker provides information only and does not provide investment, financial or legal advice.
Check another company
Search every bank, broker and alert list in one place
